公开(公告)号：US20250009742A1

公开(公告)日：2025-01-09

申请号：US18699156

申请日：2022-10-12

Applicant: AM SCIENCES INC ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Nakcheol JEONG ,  Misun LEE ,  Heewoo SIM ,  Myungjin KIM ,  Jung-Hee KIM ,  Soo Bong HAN ,  Young Sik JUNG ,  Hye jin KIM ,  Chang Soo YUN ,  Heeyeong CHO ,  Mee Hyein KIM ,  Joo Youn LEE

IPC: A61K31/501 ,  A61K31/4155 ,  A61K31/4162 ,  A61K31/422 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61P31/20 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D471/04 ,  C07D491/052 ,  C07D491/056 ,  C07D495/04

Abstract: The present invention relates to a series of novel pyrazolylmethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.

公开(公告)号：US11033571B2

公开(公告)日：2021-06-15

申请号：US16469488

申请日：2017-12-13

Applicant: AM SCIENCES INC

Inventor： Kyun Hwan Kim ,  Doo Hyun Kim ,  Yeong Min Park

IPC: A61K31/713 ,  A61P31/20 ,  A61K9/51

Abstract: The present invention relates to a pharmaceutical composition for treating or preventing hepatitis B, comprising: at least one oligonucleotide selected from the group consisting an oligonucleotide represented by a nucleic acid sequence of SEQ ID NO: 1, 2, or 6 or a nucleic acid sequence complementary thereto; and an oligonucleotide having at least one chemical modification on the oligonucleotide, as an active ingredient, and a method for screening a therapeutic agent for hepatitis B according to the formation of a G-quadruplex by HBV and a candidate material. The pharmaceutical composition forms a G-quadruplex with HBV and reduces cccDNA (covalently closed circular DNA) and thus can be used in the treatment or prevention of hepatitis B.